Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study

This pilot study examines how a drug called calaspargase pegol (Cal-PEG), used to treat childhood leukemia, affects the blood's ability to clot. The goal is to better understand and potentially prevent dangerous clotting complications that can occur during leukemia treatment. **You may be eligible if...** - You are between 2 and 21.5 years old - You have been diagnosed with acute lymphoblastic leukemia (ALL) or lymphoma - Your treatment plan includes Cal-PEG - Your parent or guardian has given consent **You may NOT be eligible if...** - You have a pre-existing blood clotting disorder - You have a known allergy to asparaginase drugs - You are outside the age range of 2–21.5 years Talk to your doctor to see if this trial is right for you.